Pacific Edge Limited (PFGTF)

Market Cap	58.07M
Revenue (ttm)	14.40M
Net Income (ttm)	-18.32M
Shares Out	n/a
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,721
Open	0.0920
Previous Close	n/a
Day's Range	0.0920 - 0.0920
52-Week Range	0.0248 - 0.0811
Beta	0.96
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 22, 2024

About Pacific Edge

Pacific Edge Limited, a cancer diagnostics company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2001
• Employees: 114
• Stock Exchange: OTCMKTS
• Ticker Symbol: PFGTF

Financial Performance

In 2023, Pacific Edge's revenue was 25.23 million, an increase of 19.95% compared to the previous year's 21.03 million. Losses were -29.54 million, 9.53% more than in 2022.

Financial numbers in NZD